文献速递外周动脉疾病

药物洗脱支架治疗股腘动脉支架内再狭窄的长期有效性:Zilver PTX日本上市后监测研究亚组分析

Long-Term Effectiveness of a Drug-Eluting Stent for Femoropopliteal In-Stent Restenosis: Subanalysis of the Zilver PTX Japan Post-Market Surveillance Study.
PubMed 文献 · J Endovasc Ther · 2020-10-21

该研究基于Zilver PTX日本上市后监测研究(NCT02254837)的亚组分析,评估Zilver PTX药物洗脱支架治疗股腘动脉支架内再狭窄(ISR)的5年结局。共纳入177例患者(204处ISR病变),平均年龄74.2±8.3岁,男性118例,糖尿病占61.0%,平均病变长度17.8±10.4 cm,完全闭塞占35.3%。5年全因死亡率为25.1%,免于临床驱动靶病变血运重建(TLR)率为73.4%,临床获益率为63.6%,Rutherford分级和踝肱指数改善持续至5年。

要点

  • Zilver PTX药物洗脱支架治疗股腘动脉ISR的5年免于TLR率为73.4%。
  • 5年全因死亡率为25.1%,未报告器械或手术相关死亡及紫杉醇相关不良事件。
  • Rutherford分级和踝肱指数改善持续至5年,临床获益率为63.6%。

核心结论

  • Zilver PTX药物洗脱支架治疗股腘动脉支架内再狭窄病变安全有效,为这一难治亚组提供了有利的治疗选择。

研究设计与样本

  • 研究为Zilver PTX日本上市后监测研究(NCT02254837)的亚组分析,该研究为前瞻性、多中心注册研究,共纳入904例症状性患者、1082处股腘动脉病变,在日本95家机构接受药物洗脱支架治疗。
  • 本亚组分析纳入177例患者(平均年龄74.2±8.3岁,男性118例)的204处ISR病变,评估5年结局。

主要发现

  • 5年全因死亡率为25.1%,未报告器械或手术相关死亡及紫杉醇相关不良事件。
  • 5年内观察到5枚支架发生断裂。
  • 5年免于临床驱动TLR率为73.4%,临床获益率为63.6%。
  • Rutherford分级和踝肱指数改善持续至5年。

关键数值与推荐

  • 患者糖尿病占61.0%(108/177),平均病变长度17.8±10.4 cm,完全闭塞占35.3%(72/204)。

临床怎么用

  • 对于股腘动脉支架内再狭窄病变,Zilver PTX药物洗脱支架可作为治疗选择之一,需关注长期TLR风险及支架断裂可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To present a subgroup analysis of patients from a large real-world study evaluating the safety and effectiveness of the Zilver PTX drug-eluting stent (DES) for treating femoropopliteal in-stent restenosis (ISR). MATERIALS AND METHODS: This study examined patients enrolled in the Zilver PTX Japan Post-Market Surveillance Study (ClinicalTrials.gov identifier NCT02254837), a prospective, multicenter registry of 904 symptomatic patients with 1082 femoropopliteal lesions treated with the DES at 95 institutions in Japan. Five-year outcomes, including mortality, stent radiography, freedom from target lesion revascularization (TLR), and clinical benefit, were evaluated for 177 patients (mean age 74.2±8.3 years; 118 men) with 204 ISR lesions treated with the Zilver DES. Over half of the patients (108, 61.0%) were diabetic. Mean lesion length was 17.8±10.4 cm, and a third (72, 35.3%) were total occlusions. Outcome measures were all-cause mortality, thrombosis, freedom from TLR, and clinical benefit, defined as freedom from persistent or deteriorating ischemic symptoms. RESULTS: No device-related or procedure-related deaths or paclitaxel-related adverse events were reported. All-cause mortality was 25.1% at 5 years. Stent fracture was observed in 5 stents through 5 years. The 5-year rate of freedom from clinically-driven TLR was 73.4%, and the rate of clinical benefit was 63.6%. Improvement in Rutherford category and ankle-brachial index was sustained through 5 years. CONCLUSION: The safety and effectiveness of the Zilver PTX stent for the treatment of femoropopliteal ISR lesions demonstrated that this device provides a favorable treatment option in this difficult-to-treat subgroup.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Sugimoto M, Komori K, Yokoi H, et al. Long-Term Effectiveness of a Drug-Eluting Stent for Femoropopliteal In-Stent Restenosis: Subanalysis of the Zilver PTX Japan Post-Market Surveillance Study. J Endovasc Ther. 2020. PMID: 33084502. doi:10.1177/1526602820966708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。